# Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

> **NCT07393204** · — · ACTIVE_NOT_RECRUITING · sponsor: **Andrés José Maria Ferreri** · enrollment: 150 (actual)

## Conditions studied

- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07393204
- **Lead sponsor:** Andrés José Maria Ferreri
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2026-12-10
- **Final completion:** 2026-12-10
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07393204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07393204, "Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07393204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*